492-27-3

Kynurenic acid (Quinurenic acid) is an endogenous tryptophan active metabolite, a triple antagonist of NMDA, glutamate, α7 nicotinic acetylcholine receptor, and an agonist of GPR35/CXCR8 with neuroprotective and anticonvulsant properties. It has neuroprotective and anticonvulsant properties and can be used to study neurodegeneration and metabolism-related diseases.

Kynurenic Acid-D5 (Standard) is a reference standard of Kynurenic Acid-D5 intended for quantitative analysis, quality control, and related biochemical research applications. Kynurenic Acid-d5 is a deuterated compound of Kynurenic Acid. Kynurenic Acid has a CAS number of 492-27-3. Kynurenic acid, a natural metabolite of tryptophan via the kynurenine pathway, is a broad-spectrum excitatory amino acid antagonist.

Kynurenic acid, an active metabolite of tryptophan, is synthesized through a kynurenine intermediate by kynurenine aminotransferases (KATs). It acts as an antagonist of both NMDA and AMPA receptors, as well as α7 nicotinic acetylcholine receptors (nAChRs; EC50s = 235, 101, and 7 µM, respectively), and functions as an agonist for the aryl hydrocarbon receptor (AhR) and G protein-coupled receptor 35 (GPR35; EC50s = 1.4 and 39 µM, respectively). In a neonatal rat model of cerebral hypoxic-ischemia, induced by carotid artery ligation, administration of kynurenic acid at 300 mg/kg prevents weight loss in the lesioned hemisphere. Additionally, at concentrations of 1 and 5 mg/ml, it protects against neurodegeneration in the rhabdomere of the eye in an Htt93QtransgenicDrosophila model of Huntington's disease. Elevated levels of kynurenic acid in the cerebrospinal fluid have been observed in patients with schizophrenia.

Kynurenic Acid-D5 is a deuterated compound of Kynurenic Acid. Kynurenic Acid (T65135) has a CAS number of 492-27-3. Kynurenic acid, a natural metabolite of tryptophan via the kynurenine pathway, is a broad-spectrum excitatory amino acid antagonist.

Kynurenic acid sodium salt is an endogenous tryptophan metabolite that acts as a broad-spectrum antagonist targeting ionotropic glutamate receptors (NMDA), other glutamate receptors, and the α7 nicotinic acetylcholine receptor, while also functioning as a potent agonist for the G-protein coupled receptor GPR35/CXCR8.